-
-
Key words:
- multiple myeloma /
- monoclonal antibody
-
-
[1] de Weers M,Tai Y,van der Veer,et al.Daratumumab,a novel therapeutic human CD38 monoclonal antibody,induces killing of multiple myeloma and other hematological tumors[J].J Immunol,2011,186:1840-1848.
[2] Overdijk M,Verploegen S,Bgels M,et al.Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma[J].Blood (ASH Annual Meeting Abstracts),2015,7:311-321.
[3] Lokhorst HM,Plesner T,Laubach JP,et al.Targeting CD38 with daratumumab monotherapy in multiple myeloma[J].N Engl J Med,2015,373:1207-1219.
[4] Lonial S,Weiss B,Usmani S,et al.Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS):an open-label,randomised,phase 2 trial[J].Lancet,2016,387:1551-1560.
[5] Dimopoulos M,Oriol A,Nahi H,et al.An open label,randomised phase 3 study of daratumumab,lenalidomide,and dexamethasone (DRD) versus lenalidomide and dexamethasone (RD) in relapsed or refractory multiple myeloma (RRMM):POLLUX[J].EHA,2016:abstract LB2238.
[6] Palumbo A,Chanan-Khan A,Weisel K,et al.Phase III randomized controlled study of daratumumab,bortezomib,and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM):CASTOR study[J].J Clin Oncol,2016,34:abstract LBA4.
[7] Martin T,Hsu K,Strickland S,et al.A phase I trial of SAR650984,a CD38 monoclonal antibody,in relapsed or refractory multiple myeloma[J].J Clin Oncol,2014b,32:abstract 8532.
[8] Martin T,Hsu K,Charpentier E,et al.A phase Ib dose escalation trial of SAR650984(Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma[J].J Clin Oncol,2014a,32:abstract 8512.
[9] Raab M,Chatterjee M,Goldschmidt H,et al.MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma:Data from clinically relevant cohorts from a phase I/IIa study[J].EHA June 9-12,2016:Abstract p279.
[10] Tai Y,Li X,Breitkreutz I,et al.Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment[J].Cancer Res,2006,66:6675-6682.
[11] Collins S,Bakan C,Swartzel G,et al.Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation:evidence for augmented NK cell function complementing ADCC[J].Cancer Immunol Immunother,2013,62:1841-1849.
[12] Zonder J,Mohrbacher A,Singhal S,et al.A phase 1,multicenter,open-label,dose escalation study of elotuzumab in patients with advanced multiple myeloma[J].Blood,2012,120:552-559.
[13] Lonial S,Dimopoulos M,Palumbo A,et al.Elotuzumab therapy for relapsed or refractory multiple myeloma[J].N Engl J Med,2015,373:621-631.
[14] Jakubowiak A,Offidani M,Pégourie B,et al.Randomized phase 2 study:elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM[J]. Blood,2016,127:2833-2840.
[15] Heffner L,Jagannath S,Zimmerman T,et al.BT062,an antibody-drug conjugate directed against cd138,given weekly for 3 weeks in each 4 week cycle:safety and further evidence of clinical activity[J].Blood (ASH Annual Meeting Abstracts),2012,120:4042.
[16] Kelly K,Siegel D,Chanan-Khan A,et al.Indatuximab ravtansine (BT062) in combination with low-dose dexamethasone and lenalidomide or pomalidomide:clinical activity in patients with relapsed/refractory multiple myeloma[J].Blood,2016,128:4486.
[17] Atanackovic D,Luetkens T,Kroger N.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma[J].Leukemia,2014,28:993-1000.
[18] San Miguel J,Mateos M,Shah J,et al.Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma[J].ASH Annual Meeting Abstracts,2015:abstract 505.
[19] Badros A,Kocoglu M,Ma N,et al.A phase II study of anti PD-1 antibody pembrolizumab,pomalidomide,and dexamethasone for relapsed/refractory multiple myeloma[J].Blood (ASH Annual Meeting Abstracts),2015,126:506.
[20] Voorhees PM,Manges RF,Sonneveld P,et al.A phase 2 multicentre study of siltuximab,an anti-interleukin-6 monoclonal antibody,in patients with relapsed or refractory multiple myeloma[J].Br J Haematol,2013,161:357-366.
[21] Orlowski RZ,Gercheva L,Williams C,et al.A phase 2,randomized,double-blind,placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma[J].Am J Hematol,2015,90:42-49.
[22] San-Miguel J,Blade J,Shpilberg O,et al.Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma[J].Blood,2014,123:4136-4142.
-
计量
- 文章访问数: 59
- PDF下载数: 35
- 施引文献: 0
下载: